Mechanism of action and pharmacological profile
The drugs in question belong to the group of non-selective inhibitors. Their main pharmacological action involves affecting the early stages of steroidogenesis. The drugs block the key process of converting cholesterol to pregnenolone. As a result of this blockade, the production of absolutely all hormonally active steroids in the body is significantly reduced.
Clinical application in adrenal pathology
The ability to suppress steroid hormone synthesis determines the main areas of application for these agents in medical practice:
- Treatment of hormonally active adrenal tumors.
- Therapy for Cushing's syndrome.
Such medications make it possible to control the excessive hormone production by the affected tissue.
Features of aminoglutethimide use in oncology
The pharmacological properties of aminoglutethimide have found application in oncological practice. It is used to treat breast carcinoma. The therapeutic effect is achieved through targeted reduction of estrogen and androgen production, which is critically important in hormone-dependent tumors.
When conducting therapy, important safety rules are taken into account:
- The drug is prescribed in mandatory combination with dexamethasone.
- Dosages above 1 g per day can cause pronounced somnolence.
- A daily dose of up to 1 g is generally well tolerated by patients.
Briefly: answers to topical questions
For what purpose is mandatory co-administration of dexamethasone required during treatment with aminoglutethimide?
The co-administration of dexamethasone is due to the non-selectivity of aminoglutethimide's action: the drug inhibits the synthesis of adrenal cortex hormones, including glucocorticoids and mineralocorticoids. Therefore, aminoglutethimide is prescribed together with dexamethasone.
What specific adverse reactions and toxic effects are characteristic of mitotane?
Mitotane is characterized by the development of side effects from the central nervous system (CNS) and the gastrointestinal tract (GIT).
Specific adverse events include:
- Teratogenicity — the drug crosses the placenta and exerts an adrenolytic effect on the fetus.
- Cumulative toxicity — the intensity and magnitude of adverse events increase as the drug accumulates in the body.
All arising toxic effects are reversible and completely disappear after discontinuation of therapy. With an insufficient dose of steroid replacement therapy, the tolerability of mitotane worsens, and side effects become more severe.
What are the absolute contraindications to prescribing mitotane?
Pregnancy occurring during mitotane therapy is contraindicated. The drug crosses the placenta and exerts an adrenolytic effect on the fetus; it possesses potential teratogenic effects. Patients receiving mitotane require effective contraception, preferably estrogen-free or barrier methods. Pregnancy planning is only possible after stopping mitotane therapy and reducing its concentration in the blood to undetectable levels; this may take 3–12 months.
What are the pharmacokinetic features of mitotane in the body?
The pharmacokinetics of mitotane are distinguished by a narrow therapeutic range and a pronounced tendency toward accumulation.
Main features:
- The blood level of mitotane depends not so much on the administered daily dose as on its accumulation associated with a long half-life.
- The decrease in mitotane concentration to undetectable levels after discontinuation of therapy may take 3–12 months.
- Dosage is limited by the need to rapidly achieve therapeutic concentration while simultaneously taking toxicity into account; the target concentration is more than 14 mg/L.
Class and exam questions
What is the common mechanism of action of mitotane and aminoglutethimide?
Both substances block the early stage of steroidogenesis — the conversion of cholesterol to pregnenolone. This leads to a general decrease in the production of all hormonally active steroids.
For which diseases are these drugs prescribed?
The main indications are Cushing's syndrome and hormonally active adrenal neoplasms.
What are the features of aminoglutethimide use in oncology?
It is used in breast carcinoma to lower androgen and estrogen levels. The drug is necessarily combined with dexamethasone.
What are the dosage limitations for aminoglutethimide?
Dosages up to 1 g per day are well tolerated, but exceeding this threshold often leads to the appearance of somnolence.
What else to study on this topic
- Detailed biochemical pathway of cholesterol conversion to pregnenolone
- Pathogenesis and clinical manifestations of Cushing's syndrome
- The role of hormonally active adrenal tumors in endocrinology
- Mechanisms of breast carcinoma development and hormone therapy
- Pharmacodynamic rationale for co-administration with dexamethasone
Master the entire topic in the «Pharmacology» course
This is a summary. The course covers everything tested in classes and exams.
- Complete study guide on "Mitotane and Aminoglutethimide" and another 5,304 pages of the subject
- Assignments and quizzes after every topic — just like in a colloquium
- AI tutor answers questions on the topic anytime
- 116 video lessons on the subject
Other topics in the section "Hormone preparations, their synthetic substitutes, and antagonists"
Free video lessons: pharmacologyShort lessons with study notes — no registration required.
Prepared by WhiteCoat Pro faculty in accordance with the medical school curriculum. For educational purposes only.